Provention Bio Stock Forecast, Price & News

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio or view top-rated stocks.

How has Provention Bio's stock price been impacted by COVID-19?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRVB stock has decreased by 51.5% and is now trading at $4.37.
View which stocks have been most impacted by COVID-19.

Are investors shorting Provention Bio?

Provention Bio saw a increase in short interest in November. As of November 30th, there was short interest totaling 2,880,000 shares, an increase of 18.5% from the November 15th total of 2,430,000 shares. Based on an average daily volume of 549,700 shares, the days-to-cover ratio is currently 5.2 days. Approximately 5.4% of the shares of the stock are sold short.
View Provention Bio's Short Interest.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.08. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. During the same period last year, the firm earned ($0.56) EPS.
View Provention Bio's earnings history.

What price target have analysts set for PRVB?

8 equities research analysts have issued 12 month price targets for Provention Bio's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Provention Bio's share price to reach $17.75 in the next year. This suggests a possible upside of 306.2% from the stock's current price.
View analysts' price targets for Provention Bio or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:

• Ashleigh W. Palmer, Chief Executive Officer & Director
• Christina Yi, Chief Operating Officer
• Thierry Chauche, Chief Financial Officer
• Francisco Leon, Chief Scientific Officer
• Eleanor Leni Ramos, Chief Medical Officer

Who are some of Provention Bio's key competitors?

Some companies that are related to Provention Bio include PureTech Health (PRTC), Rani Therapeutics (RANI), Axsome Therapeutics (AXSM), Vectura Group (VEGPF), Merus (MRUS), CannTrust (CNTTF), Reata Pharmaceuticals (RETA), MannKind (MNKD), Revance Therapeutics (RVNC), Vaxxinity (VAXX), Organogenesis (ORGO), Crinetics Pharmaceuticals (CRNX), Zealand Pharma A/S (ZEAL), BELLUS Health (BLUSF) and Day One Biopharmaceuticals (DAWN).
View all of PRVB's competitors.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends for Provention Bio.

Which major investors are buying Provention Bio stock?

PRVB stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, and Jason Hoitt.
View insider buying and selling activity for Provention Bio or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $4.37.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $276.95 million. The company earns $-98.58 million in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 59 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

Where are Provention Bio's headquarters?

Provention Bio is headquartered at P.O. BOX 666, OLDWICK NJ, 08858.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at (908) 428-9136 or via email at [email protected].